Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
8.73
0.00 (0.06%)
Oct 30, 2026, 9:41 AM EDT - Market open
Moleculin Biotech Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 7.26 | 8.88 | 4.28 | 23.55 | 43.15 | 70.9 |
Cash & Short-Term Investments | 7.26 | 8.88 | 4.28 | 23.55 | 43.15 | 70.9 |
Cash Growth | -3.90% | 107.53% | -81.83% | -45.42% | -39.15% | 367.30% |
Other Receivables | 0 | 0.01 | 0.02 | 0.1 | 0.02 | 0.05 |
Receivables | 0 | 0.01 | 0.02 | 0.1 | 0.02 | 0.05 |
Prepaid Expenses | 1.07 | 0.52 | 0.57 | 2.08 | 1.63 | 1.06 |
Other Current Assets | 0.39 | 0.28 | 0.33 | 0.55 | 0.8 | 0.49 |
Total Current Assets | 8.72 | 9.69 | 5.19 | 26.27 | 45.6 | 72.5 |
Property, Plant & Equipment | 0.32 | 0.39 | 0.58 | 0.8 | 0.68 | 0.45 |
Other Intangible Assets | 11.15 | 11.15 | 11.15 | 11.15 | 11.15 | 11.15 |
Other Long-Term Assets | 0.9 | 0.9 | - | - | - | - |
Total Assets | 21.09 | 22.13 | 16.93 | 38.22 | 57.42 | 84.09 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.34 | 3.51 | 2.03 | 2.5 | 2.1 | 1.36 |
Accrued Expenses | 4.83 | 3.21 | 3.21 | 4.22 | 2.61 | 2.16 |
Current Portion of Leases | 0.15 | 0.14 | 0.12 | 0.1 | 0.12 | 0.1 |
Total Current Liabilities | 9.31 | 6.85 | 5.36 | 6.82 | 4.82 | 3.62 |
Long-Term Leases | 0.15 | 0.22 | 0.36 | 0.47 | 0.34 | 0.06 |
Other Long-Term Liabilities | 0.04 | 0.04 | - | 4.86 | 0.08 | 1.41 |
Total Liabilities | 9.5 | 7.12 | 5.72 | 12.14 | 5.23 | 5.1 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0 | - | 0.03 | 0.03 | 0.03 |
Additional Paid-In Capital | 238.13 | 221 | 183.69 | 157.65 | 153.99 | 151.73 |
Retained Earnings | -226.48 | -206 | -172.44 | -131.6 | -101.84 | -72.81 |
Comprehensive Income & Other | -0.06 | 0.01 | -0.04 | -0.01 | 0.01 | 0.04 |
Shareholders' Equity | 11.59 | 15.01 | 11.21 | 26.07 | 52.19 | 78.99 |
Total Liabilities & Equity | 21.09 | 22.13 | 16.93 | 38.22 | 57.42 | 84.09 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.29 | 0.36 | 0.48 | 0.57 | 0.45 | 0.16 |
Net Cash (Debt) | 6.97 | 8.52 | 3.8 | 22.98 | 42.69 | 70.74 |
Net Cash Growth | -2.34% | 124.18% | -83.46% | -46.18% | -39.65% | 374.92% |
Net Cash Per Share | 41.13 | 143.83 | - | - | - | - |
Filing Date Shares Outstanding | 0.97 | 0.27 | 0.03 | - | - | - |
Total Common Shares Outstanding | 0.36 | 0.16 | - | - | - | - |
Working Capital | -0.59 | 2.83 | -0.17 | 19.46 | 40.78 | 68.88 |
Book Value Per Share | 32.64 | 93.81 | - | - | - | - |
Tangible Book Value | 0.44 | 3.86 | 0.06 | 14.93 | 41.04 | 67.85 |
Tangible Book Value Per Share | 1.24 | 24.12 | - | - | - | - |
Machinery | - | 1.18 | 1.16 | 1.17 | 1.04 | 0.98 |